Preemptive administration of levosimendan (especially at 12 μg/kg) before cardiopulmonary bypass reduced pulmonary artery pressure and improved right ventricular function in patients with PH.
RCT (n=30)
Randomized
Does preemptive administration of levosimendan improve hemodynamic and echocardiographic parameters in adult patients with pulmonary hypertension undergoing cardiac surgery?
Preemptive administration of levosimendan at 12 μg/kg before cardiopulmonary bypass effectively reduces pulmonary artery pressure and improves right ventricular function in patients with preexisting pulmonary hypertension.
INTRODUCTION: The perioperative management of patients with pulmonary hypertension (PH) undergoing cardiac surgery represents one of the most challenging clinical scenarios. This fact mainly depends on the relationship existing between PH and right ventricular failure (RVF). Levosimendan (LS) is an inodilator that might be an effective agent in the treatment of PH and RVF. The aim of this study was to examine the impact of the duration of cardiopulmonary bypass (CPB) on the therapeutic drug monitoring of LS and to evaluate the effect of preemptive administration of LS on perioperative hemodynamic and echocardiographic parameters in cardiac surgical patients with preexisting PH. MATERIALS AND METHODS: In this study, LS was administered in adult patients undergoing cardiac surgery before CPB in order to prevent exacerbation of preexisting PH and subsequent right ventricular dysfunction. Thirty cardiac surgical patients with preoperatively confirmed PH were randomized to receive either 6 μg/kg or 12 μg/kg of LS after the induction of anesthesia. The plasma concentration of LS was measured after CPB. In this study, a low sample volume was used combined with a simple sample preparation protocol. The plasma sample was extracted by protein precipitation and evaporated; then, the analyte was reconstituted and detected using specific and sensitive bioanalytical liquid chromatography with mass spectrometry (LC-MS/MS) methodology. The clinical, hemodynamic, and echocardiographic parameters were registered and evaluated before and after the administration of the drug. RESULTS: A fast bioanalytical LC-MS/MS methodology (a run time of 5.5 min) was developed for the simultaneous determination of LS and OR-1896, its main metabolite in human plasma. The LC-MS/MS method was linear over a range of 0.1-50 ng/mL for LS and 1-50 ng/mL for its metabolite OR-1896. Measured plasma concentrations of LS were inversely related to the duration of CPB. LS administration before CPB during cardiac surgery was effective in reducing pulmonary artery pressure and improving hemodynamic parameters after CPB, with a more pronounced and durable effect of the drug at the dose of 12 μg/kg. Additionally, administration of LS at a dose of 12 μg/kg in cardiac surgical patients with PH before CPB improved right ventricular function. CONCLUSION: LS administration decreases pulmonary artery pressure and may improve right ventricular function in patients with PH undergoing cardiac surgery.
Ftikos et al. (Tue,) conducted a rct in Pulmonary hypertension in patients undergoing cardiac surgery (n=30). Levosimendan vs. Levosimendan 6 μg/kg was evaluated on Plasma concentration of levosimendan, hemodynamic and echocardiographic parameters. Preemptive administration of levosimendan (especially at 12 μg/kg) before cardiopulmonary bypass reduced pulmonary artery pressure and improved right ventricular function in patients with PH.